Citation

Campos Muñoz L, De Unamuno Bustos B, Herranz Pinto P, El Ahmed HH, Ruiz-Villaverde R, Taberner Ferrer R. Am. J. Clin. Dermatol. 2014; 15(Suppl 1): S17-S24.

Copyright

(Copyright © 2014, Springer International)

DOI

10.1007/s40257-013-0055-3

PMID

unavailable

Abstract

Psoriasis is a systemic chronic inflammatory disease that affects 1-3% of the world's population. Knowledge of the pathogenesis of psoriasis, particularly in the understanding of the role of T cells and tumor necrosis factor α (TNFα), and advances in immunology have led to the development of biological agents, which, due to their great effectiveness, speed of response and good tolerability, have revolutionized patient management. One of these is infliximab, a human chimeric immunoglobulin G1 monoclonal antibody composed of human antibody constant regions and murine variable regions that was developed specifically to target TNFα. The six cases presented in this series highlight the feasibility, efficacy and safety of infliximab for psoriasis when administered in a variety of patients in several infusion centers across Spain. All six patients showed improvement in their psoriasis after the initiation of infliximab and no significant tolerability issues or injection site reactions were reported, despite the presence of several comorbid conditions or patient characteristics that traditionally reduce the efficacy of psoriasis treatments. This suggests that while the management of psoriasis patients with comorbid conditions and various unfavorable prognostic characteristics requires a multidisciplinary approach to ensure the patient obtains the best therapeutic response, infliximab is an effective and well tolerated treatment in these patients. © Springer International Publishing 2014.

Language: en

Keywords

Humans; Adult; Aged; Female; Male; Middle Aged; adult; Spain; human; female; male; aged; Treatment Outcome; alcoholism; case report; depression; schizophrenia; suicide attempt; treatment outcome; comorbidity; disease severity; Psoriasis; Ambulatory Care; Infusions, Intravenous; obesity; article; smoking; clinical article; serology; clinical feature; patient care; priority journal; ambulatory care; physical examination; middle aged; pathology; drug safety; mental patient; drug efficacy; drug tolerability; drug withdrawal; multicenter study; corticosteroid; hypertension; psoriasis; arthralgia; pruritus; phototherapy; insulin dependent diabetes mellitus; immunology; intravenous drug administration; laboratory test; tumor necrosis factor alpha; case management; thorax radiography; add on therapy; treatment response; blood analysis; arthritis; Article; interdisciplinary communication; Interdisciplinary Communication; dyslipidemia; etretin; hypertriglyceridemia; methotrexate; Dermatologic Agents; dermatological agent; metabolic syndrome X; injection site reaction; clinical effectiveness; feasibility study; hospital readmission; cyclosporin; infliximab; procedures; indometacin; Antibodies, Monoclonal; efalizumab; etanercept; absence of side effects; psoriasis vulgaris; adalimumab; skin defect; psoralen; monoclonal antibody; psoriatic arthritis; Tumor Necrosis Factor-alpha; chronic kidney disease; antagonists and inhibitors; corticosteroid therapy; erythroderma; ustekinumab; biological product; erythrodermic psoriasis; immunoglobulin G1; Psoriasis Area and Severity Index; tuberculin test